Upstream Bio, Inc.
corporate_fare Company Profile
Upstream Bio, Inc. (NASDAQ:UPB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for UPB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-01, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for UPB spans 8-K, 10-Q, 424B5, 10-K.
Recent high-impact activity:
- Upstream Bio Finalizes Phase 3 Plans for Verekitug in Severe Asthma and CRSwNP
- Upstream Bio Finalizes Phase 3 Plans for Verekitug in Severe Asthma and CRSwNP
- Upstream Bio Reports Q2 2026: $261M Cash, Phase 3 Starts in Q1 2027
- Upstream Bio Q2 2026: $261M Cash, Phase 3 Trials on Track for Q1 2027, COPD Enrollment Complete
- Upstream Bio's Verekitug Shows Clinically Meaningful Improvements in 79% of Patients in New Phase 2 CRSwNP Data
Financial Snapshot
Short Interest & Short Volume
2.70 days to coverFINRA reported short interest of 3,550,200 shares in UPB as of the October 30, 2026 settlement, a 20.8% decrease from the prior period — about 2.7 days to cover at its recent average daily volume. On November 20, 2026, 60.1% of UPB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.